Answers are grounded in this paper and cite their sources.
This neoantigen-targeting peptide nanoshield improves tumor immunity in glioma, suggesting enhanced postoperative treatment alternatives.
Despite advances in immunotherapy, its efficacy against postoperative glioma recurrence remains limited. Here, we present a neoantigen-targeting peptide nanoshield that synergizes with glioma resection to eliminate residual tumor cells and prevent relapse. The nanoshield architecture is constructed using a multicationic protein (MCP) as the structural scaffold, which is assembled with the mutated isocitrate dehydrogenase 1 (muIDH1) neoantigen. The nanoshield vaccine enables lysosome-escaping muIDH1 delivery and inflammasome-mediated immune activation, generating polyfunctional CD8+ T cells. The results demonstrate superior and durable immunogenicity, with a 3-fold increase in CD8+ T cells and a 6-fold in vivo retention profile compared to free peptide controls, respectively. This leads to significant reduction in tumor size in prophylactic and therapeutic glioma models. Notably, it achieves over 40% improvement in terms of postoperative recurrence-free survival through combining the nanovaccine with antiprogrammed death-1 (aPD-1) therapy. Our immunotherapeutic strategy induces potent antitumor immunity, offering promising clinical potential for postoperative management.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: